Outlook Therapeutics(US:OTLK) Globenewswire·2026-03-05 21:15Core Viewpoint - Outlook Therapeutics, Inc. is focused on enhancing the standard of care for bevacizumab in treating retina diseases and is actively engaging with the FDA to address issues raised in the Complete Response Letter for its Biologics License Application for ONS-5010/LYTENAVA™ [1][3] Regulatory Update - A Type A meeting with the FDA was held to clarify the outstanding issues regarding the evidence of effectiveness and to discuss potential regulatory pathways for approval [2] - The company aims to align with the FDA on confirmatory evidence supporting its application and to identify the most efficient pathway toward potential approval [3] Clinical Trial Results - ONS-5010/LYTENAVA™ showed clinically meaningful and statistically significant improvements in visual acuity in the NORSE TWO Phase 3 trial, meeting its primary and key secondary endpoints [4] - The NORSE EIGHT trial and other submitted information provided confirmatory evidence of efficacy and safety, supporting the successful NORSE TWO trial [4] Product Potential - If approved, ONS-5010/LYTENAVA™ would be the first FDA-approved ophthalmic formulation of bevacizumab, backed by standardized manufacturing and robust pharmacovigilance [5] - The product candidate is supported by a fully domestic, end-to-end U.S. manufacturing supply chain [5] Product Description - ONS-5010/LYTENAVA™ is an ophthalmic formulation of bevacizumab produced in the U.S. for treating wet AMD and has received Marketing Authorization in the EU and UK [6] - In the U.S., ONS-5010/LYTENAVA™ is currently investigational and, if approved, would be the first ophthalmic formulation of bevacizumab for retinal indications [10] Mechanism of Action - Bevacizumab-vikg is a recombinant humanized monoclonal antibody that binds to all isoforms of human VEGF, neutralizing its biological activity and reducing endothelial cell proliferation and vascular leakage in the retina [8]